On Wednesday, JMP Securities adjusted its share price target for Crinetics Pharmaceuticals (NASDAQ:CRNX), increasing it to $80 from the previous $60, while maintaining a Market Outperform rating. This ...
Investing.com - Citizens JMP has reiterated its Market Outperform rating and $5.00 price target on Teads Holding (NASDAQ:TEAD), a digital advertising company with a market capitalization of $160.5 ...
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback